Donepezil Dosage
Start donepezil at 5 mg once daily in the evening, then increase to 10 mg once daily after 4-6 weeks if tolerated; no dose adjustment is required for hepatic or renal impairment. 1
Standard Dosing Regimen
The FDA-approved dosing strategy is straightforward:
- Initial dose: 5 mg once daily, taken in the evening just prior to bedtime 1
- Maintenance dose: After 4-6 weeks at 5 mg, consider increasing to 10 mg once daily 1
- Administration: Can be taken with or without food 1
Rationale for Dose Escalation Timing
The 4-6 week waiting period before escalating to 10 mg is critical because:
- Steady-state plasma concentrations are not achieved until 15 days of daily dosing 1
- The incidence of cholinergic adverse events (nausea, vomiting, diarrhea) is directly influenced by the rate of dose escalation 1
- Open-label trials using 6-week titration showed similar adverse event frequencies between 5 mg and 10 mg doses, whereas 1-week titration resulted in higher adverse events at 10 mg 1
The 10 mg dose may provide additional benefit for some patients, though the difference from 5 mg did not reach statistical significance in controlled trials. 1 The decision to escalate is based on individual tolerability and clinical judgment rather than mandatory efficacy gains.
Hepatic Impairment
No dose adjustment is necessary for patients with hepatic impairment. 1, 2
The evidence supporting this recommendation:
- In patients with stable alcoholic cirrhosis, donepezil clearance decreased by only 20% compared to healthy controls 3
- A formal pharmacokinetic study in 10 patients with chronic compensated cirrhosis showed the only statistically significant difference was a 37.5% increase in Cmax (6.6 vs 4.8 ng/mL), which was not clinically significant 2
- AUC increases were minimal (7-21%) and not statistically significant 2
- The drug was equally well tolerated in hepatically impaired patients 2
Renal Impairment
No dose adjustment is necessary for patients with renal impairment, including severe renal dysfunction. 1
Supporting evidence:
- In 4 patients with moderate to severe renal impairment (ClCr <22 mL/min/1.73 m²), donepezil clearance did not differ from age- and sex-matched healthy subjects 1
- Donepezil is approximately 57% excreted in urine (with only 17% as unchanged drug) and 15% in feces, with extensive hepatic metabolism 1
- The drug has been shown safe and well tolerated in patients with moderately to severely impaired renal function 4, 5
Common Pitfalls to Avoid
Escalating too quickly: Rushing from 5 mg to 10 mg within 1-2 weeks significantly increases cholinergic adverse events 1
Discontinuing prematurely: Adverse events are typically mild, transient, and resolve with continued administration 6. Most are cholinergic in nature (nausea, vomiting, diarrhea) and occur early in treatment 5, 7
Unnecessary dose reductions in organ impairment: Unlike many medications, donepezil requires no adjustment for hepatic or renal disease, even in severe cases 1, 2
Timing concerns: If insomnia or sleep disturbances occur with evening dosing, switching to morning administration can reduce these events to placebo levels 5
Pharmacokinetic Considerations
Donepezil has favorable pharmacokinetic properties that support its simple dosing:
- Half-life: Approximately 70 hours, supporting once-daily dosing 1
- Bioavailability: 100% with oral administration 1
- Time to peak: 3-4 hours 1, 4
- Protein binding: 96% (mainly albumin and α1-acid glycoprotein) 1
- Metabolism: Primarily via CYP2D6 and CYP3A4 1
- Drug interactions: Minimal, with no clinically significant interactions with highly protein-bound drugs like warfarin, digoxin, or furosemide 1, 5